Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Non-Current Liabilities data on file, last reported at $397.0 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 8.28% year-over-year to $397.0 million in Q1 2026; TTM through Mar 2026 was $397.0 million, a 8.28% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 270.78% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $397.0 million, down from $1.6 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RARE reached as high as $1.6 billion in Q4 2025 and fell as low as $232.0 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $772.8 million across 5 years, with a median of $638.8 million in 2022.
• Across the five-year window, Total Non-Current Liabilities surged 464.18% in 2022 and tumbled 72.43% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.2 billion in 2022, then sank by 70.27% to $353.3 million in 2023, then advanced by 19.17% to $421.0 million in 2024, then surged by 270.78% to $1.6 billion in 2025, then slumped by 74.57% to $397.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $397.0 million in Q1 2026, $1.6 billion in Q4 2025, and $1.2 billion in Q3 2025.